NCT06120348RecruitingNot Applicable
Multi-center, Placebo-controlled, Randomized, Parallel Design, Superiority, Pivotal Clinical Trial to Evaluate the Efficacy and Safety of Application of Electrical Stimulation Around Eye After Laser Keratoplasty (LASEK) in Patients With Dry Eye Syndrome.
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Nu Eyne Co., Ltd.
- Enrollment
- 178
- Locations
- 6
- Primary Endpoint
- Changes in Tear break-up time (T-BUT)
Study Overview
Brief Summary
This study aims to evaluate the efficacy and safety of applying pulse Electrical Stimulation around eye after laser keratoplasty (LASEK) in patients with dry eye syndrome.
Detailed Description
Duration of study period (per participant): Screening period (0-4weeks). Intervention period (12weeks).
Patient needs to visit site at least 8 times (Screening, baseline, 1 day, 3day, 1, 4, 8, 12weeks based on baseline). Baseline visit will be done on the day of surgery.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 19 Years to 60 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Men and women aged 19 to 60
- •Those who are scheduled to get LASEK surgery
- •Those who have had dry eye symptoms for more than 3 months.
- •According to the guidelines for diagnosing dry eye syndrome of Korean Corneal Disease Study Group, those who fall under Grade II or higher
- •Those who TBUT test results of less than 10 seconds
- •Those who OSDI score of 13 or higher
- •Those who agreed to use contraception using a medically acceptable method during the period of clinical trial among Women of child bearing potential (WOCBP).
- •A person who voluntarily agreed to participate in this clinical trial.
Exclusion Criteria
- •A person who has applied cyclosporin for the treatment of dry eye syndrome, drugs such as lipid-containing eye drops, topical steroid eye drops, IPL, etc., and medical devices for the treatment of dry eye syndrome within one month from the screening
- •A person with an uncontrollable systemic chronic disease.
- •Those who are allergic to drugs such as Fluorescein Solution or ophthalmic anesthetics
- •In a case where there is a history of receiving ophthalmic surgery known to affect the tear layer within the last 6 months (e.g., Cataract, Punctal plug insertion, Pterygium surgery)
- •A person who has eyelid diseases or structural abnormalities
- •A person with acute eye infection or inflammation of the eyeball not related to Meibomian gland dysfunction
- •A person with abnormalities in the eyelids or eyelashes
- •A person with an eye condition or ophthalmic disease that is considered unsuitable for surgery
- •A person who takes systemic drugs (e.g., tetracycline derivatives, antihistamine, isotretinoin)
- •Pregnant or lactating women
- •Those who can't understand or read the consent form of this clinical trial (e.g., illiterate or foreigners)
- •Any other cases that PI considers hard to participate in this clinical trial (e.g., heart-related problems, seizure, epilepsy. Patients transplanted metal or electronic device in head & neck. Patient suffering from unknown pain. Patients who are warned not to use our clinical trial device or is prohibited from using it (e.g., pacemaker user).)
- •Those who wore contact lenses within 72 hours before screening or who must wear contact lenses during the clinical trial period
- •Those who have taken the relevant systemic drugs (steroids, immunosuppressants, omega-3 and anticholinergic drugs, etc.) within 30 days from the date of screening
- •Those who are judged to have problems attaching electrodes due to inflammatory reactions or other dermatological problems in the skin around the orbit where the electrodes of medical devices are attached
- •Those who participated in other clinical trial within 30 days from the screening date
Arms & Interventions
Experimental Group
Experimental
Charge-Balanced, Symmetric Nerve Stimulation device 30 mins once a day for 4weeks(28days) and twice a week from the 5weeks to the 12 weeks.
Intervention: Charge-Balanced, Symmetric Nerve Stimulation (Device)
Control Group
Sham Comparator
Sham device 30 mins once a day for 4weeks(28days) and twice a week from the 5weeks to the 12 weeks.
Intervention: Sham Stimulation (Device)
Outcomes
Primary Outcomes
Changes in Tear break-up time (T-BUT)
Time Frame: baseline, 12 weeks
Check the changes in Tear break-up time (T-BUT)
Changes in Visual Analogue Scale (VAS) score
Time Frame: baseline, 1 week
Check the changes in Visual Analogue Scale (VAS) score
Secondary Outcomes
- Changes in Tear break-up time (T-BUT)(baseline, 1, 4, 8 weeks)
- Changes in 5-Item Dry Eye Questionnaire (DEQ-5) and Ocular Surface Disease Index (OSDI) score(baseline, 1, 4, 8, 12 weeks)
- Changes in Visual Analogue Scale (VAS) score(baseline, 3 days, 4, 8, 12 weeks)
- Changes in Tear Volume(baseline, 1, 4, 8, 12 weeks)
- Changes in Staining Score(baseline, 1, 4, 8, 12 weeks)
- Changes in the length of the aesthesiometer's filament in centimeters(baseline, 1, 4, 8, 12 weeks)
Investigators
Study Sites (6)
Loading locations...
Similar Trials
Recruiting
Not Applicable
Study of Application of Transcutaneous Pulsed Electrical Stimulation Around Eye in Age-related Macular DegenerationEarly to Moderate Dry Age-Related Macular DegenerationNCT05259371Nu Eyne Co., Ltd.25
Completed
Not Applicable
Study of Application of Pulse Electrical Stimulation Around Eye in Glaucoma PatientsGlaucomaNCT05159414Nu Eyne Co., Ltd.18
Completed
Not Applicable
Application of Pulse Electrical Stimulation Around Eye in Dry Eye Disease Patients Scheduled for LASEK SurgeryDry Eye DiseaseNCT05271422Nu Eyne Co., Ltd.24
Unknown
Not Applicable
BCI Driving FES and Hand Orthosis for Upper Limb Rehabilitation in Chronic StrokeStroke, CerebrovascularHemiplegia and HemiparesisStroke/Brain AttackNCT06179745University of Essex32
Unknown
Not Applicable
Effect of Percutaneous Acupoint Electrical Stimulation on DeliriumDelirium, PostoperativeNCT06360549Qin Zhang238